|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
US8986672B2
(en)
*
|
2005-06-23 |
2015-03-24 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
US20100086522A1
(en)
*
|
2006-07-18 |
2010-04-08 |
Ottawa Health Research Institute |
Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
|
|
US20090317456A1
(en)
*
|
2006-10-13 |
2009-12-24 |
Medigene Ag |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
US8450106B2
(en)
*
|
2007-10-17 |
2013-05-28 |
The Ohio State University Research Foundation |
Oncolytic virus
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
US20130280170A1
(en)
|
2012-04-20 |
2013-10-24 |
Aladar A. Szalay |
Imaging methods for oncolytic virus therapy
|
|
WO2014055960A1
(en)
|
2012-10-05 |
2014-04-10 |
Genelux Corporation |
Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
EP3207130B1
(en)
|
2014-10-14 |
2019-08-07 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
MX2017008013A
(es)
*
|
2014-12-18 |
2018-03-06 |
Amgen Inc |
Formulacion congelada estable de virus de herpes simple.
|
|
GB201504251D0
(en)
*
|
2015-03-13 |
2015-04-29 |
Virttu Biolog Ltd And University Of Sheffield The |
Oncolytic herpes simplex virus infected cells
|
|
WO2016164370A1
(en)
*
|
2015-04-06 |
2016-10-13 |
Ohio State Innovation Foundation |
Egfr-directed car therapy for glioblastoma
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
AU2018219895C1
(en)
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
US11576872B2
(en)
|
2017-05-08 |
2023-02-14 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
CN112004923A
(zh)
|
2017-11-22 |
2020-11-27 |
迈索布拉斯特国际有限公司 |
细胞组合物及治疗方法
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CN108070569A
(zh)
*
|
2018-02-05 |
2018-05-25 |
翁炳焕 |
一种产前基因芯片检测的改良方法
|
|
SG11202007606QA
(en)
|
2018-02-17 |
2020-09-29 |
Flagship Pioneering Innovations V Inc |
Compositions and methods for membrane protein delivery
|
|
US20210228627A1
(en)
|
2018-05-15 |
2021-07-29 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
ES2966045T3
(es)
|
2018-06-04 |
2024-04-18 |
Calidi Biotherapeutics Inc |
Vehículos basados en células para la potenciación de la terapia viral
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
CA3105953A1
(en)
|
2018-07-09 |
2020-01-16 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
EP3875119A4
(en)
*
|
2018-10-30 |
2022-08-31 |
The University of Tokyo |
ONCOLYTIC VIRUS FOR CANCER THERAPY
|
|
AU2019377141B2
(en)
|
2018-11-06 |
2024-06-06 |
Calidi Biotherapeutics (Nevada), Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
|
CA3120282A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
EP3880179A2
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
US20230043255A1
(en)
|
2018-11-14 |
2023-02-09 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for t cell delivery
|
|
KR20210131991A
(ko)
|
2018-11-14 |
2021-11-03 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
구획-특이적 카고 전달을 위한 조성물 및 방법
|
|
CN113891934A
(zh)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
|
|
TW202038947A
(zh)
|
2018-11-28 |
2020-11-01 |
德商創新分子有限責任公司 |
在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
MX2021007639A
(es)
|
2018-12-27 |
2021-08-11 |
Amgen Inc |
Formulaciones de virus liofilizadas.
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CN114258398A
(zh)
|
2019-06-13 |
2022-03-29 |
总医院公司 |
工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
|
|
CA3149478A1
(en)
|
2019-08-05 |
2021-02-11 |
Mesoblast International Sarl |
Cellular compositions comprising viral vectors and methods of treatment
|
|
WO2021087019A1
(en)
*
|
2019-11-01 |
2021-05-06 |
University Of Houston System |
Oncolytic virotherapy with induced anti-tumor immunity
|
|
CN116368221A
(zh)
|
2020-04-22 |
2023-06-30 |
因达普塔治疗公司 |
自然杀伤(nk)细胞组合物及其生成方法
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
BR112023001272A2
(pt)
|
2020-07-24 |
2023-04-04 |
Massachusetts Gen Hospital |
Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
|
|
CN115996735A
(zh)
|
2020-08-10 |
2023-04-21 |
迈索布拉斯特国际有限公司 |
细胞组合物和治疗方法
|
|
US20230303665A1
(en)
|
2020-08-28 |
2023-09-28 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
US20250230511A1
(en)
|
2021-10-29 |
2025-07-17 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
|
KR20240130158A
(ko)
|
2021-12-03 |
2024-08-28 |
더 브로드 인스티튜트, 인코퍼레이티드 |
효율적인 생체내 전달을 위한 조성물 및 방법
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025519070A
(ja)
|
2022-05-17 |
2025-06-24 |
エンヴェロップ セラピューティクス， インコーポレイテッド |
効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|